


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">31198410</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">1477-9560</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>17</Volume>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Thrombosis journal</Title>
                <ISOAbbreviation>Thromb J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A brief review on resistance to P2Y<sub>12</sub> receptor antagonism in coronary artery disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12959-019-0197-5</ELocationID>
            <Abstract>
                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Platelet inhibition is important for patients with coronary artery disease. When dual antiplatelet therapy (DAPT) is required, a P2Y<sub>12</sub>-antagonist is usually recommended in addition to standard aspirin therapy. The most used P2Y<sub>12</sub>-antagonists are clopidogrel, prasugrel and ticagrelor. Despite DAPT, some patients experience adverse cardiovascular events, and insufficient platelet inhibition has been suggested as a possible cause. In the present review we have performed a literature search on prevalence, mechanisms and clinical implications of resistance to P2Y<sub>12</sub> inhibitors.</AbstractText>
                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">The PubMed database was searched for relevant papers and 11 meta-analyses were included. P2Y<sub>12</sub> resistance is measured by stimulating platelets with ADP ex vivo and the most used assays are vasodilator stimulated phosphoprotein (VASP), Multiplate, VerifyNow (VN) and light transmission aggregometry (LTA).</AbstractText>
                <AbstractText Label="Discussion/conclusion" NlmCategory="UNASSIGNED">The frequency of high platelet reactivity (HPR) during clopidogrel therapy is predicted to be 30%. Genetic polymorphisms and drug-drug interactions are discussed to explain a significant part of this inter-individual variation. HPR during prasugrel and ticagrelor treatment is estimated to be 3-15% and 0-3%, respectively. This lower frequency is explained by less complicated and more efficient generation of the active metabolite compared to clopidogrel. Meta-analyses do show a positive effect of adjusting standard clopidogrel treatment based on platelet function testing. Despite this, personalized therapy is not recommended because no large-scale RCT have shown any clinical benefit. For patients on prasugrel and ticagrelor, platelet function testing is not recommended due to low occurrence of HPR.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Warlo</LastName>
                    <ForeName>Ellen M K</ForeName>
                    <Initials>EMK</Initials>
                    <Identifier Source="ORCID">0000-0002-4479-379X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>1Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Pb 4956 Nydalen, 0424 Oslo, Norway.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 0389 8485</Identifier>
                        <Identifier Source="GRID">grid.55325.34</Identifier>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>2Faculty of Medicine, University of Oslo, Oslo, Norway.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 1936 8921</Identifier>
                        <Identifier Source="GRID">grid.5510.1</Identifier>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>3Center for Heart Failure Research, University of Oslo, Oslo, Norway.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 1936 8921</Identifier>
                        <Identifier Source="GRID">grid.5510.1</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arnesen</LastName>
                    <ForeName>Harald</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>1Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Pb 4956 Nydalen, 0424 Oslo, Norway.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 0389 8485</Identifier>
                        <Identifier Source="GRID">grid.55325.34</Identifier>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>2Faculty of Medicine, University of Oslo, Oslo, Norway.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 1936 8921</Identifier>
                        <Identifier Source="GRID">grid.5510.1</Identifier>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>3Center for Heart Failure Research, University of Oslo, Oslo, Norway.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 1936 8921</Identifier>
                        <Identifier Source="GRID">grid.5510.1</Identifier>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seljeflot</LastName>
                    <ForeName>Ingebj√∏rg</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>1Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Pb 4956 Nydalen, 0424 Oslo, Norway.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 0389 8485</Identifier>
                        <Identifier Source="GRID">grid.55325.34</Identifier>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>2Faculty of Medicine, University of Oslo, Oslo, Norway.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 1936 8921</Identifier>
                        <Identifier Source="GRID">grid.5510.1</Identifier>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>3Center for Heart Failure Research, University of Oslo, Oslo, Norway.</Affiliation>
                        <Identifier Source="ISNI">0000 0004 1936 8921</Identifier>
                        <Identifier Source="GRID">grid.5510.1</Identifier>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Thromb J</MedlineTA>
            <NlmUniqueID>101170542</NlmUniqueID>
            <ISSNLinking>1477-9560</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Clopidogrel</Keyword>
            <Keyword MajorTopicYN="N">P2Y12 receptor antagonists</Keyword>
            <Keyword MajorTopicYN="N">Prasugrel</Keyword>
            <Keyword MajorTopicYN="N">Residual platelet reactivity</Keyword>
            <Keyword MajorTopicYN="N">Ticagrelor</Keyword>
        </KeywordList>
        <CoiStatement>Competing interestsThe authors declare that they have no competing interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31198410</ArticleId>
            <ArticleId IdType="doi">10.1186/s12959-019-0197-5</ArticleId>
            <ArticleId IdType="pii">197</ArticleId>
            <ArticleId IdType="pmc">PMC6558673</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

